This large-scale, multi-centre trial involved 800 symptomatic patients recruited across four NHS hospitals—Exeter, Shrewsbury, Oxford, and Cornwall. ORI-02 aimed to demonstrate that Oricol could detect colorectal cancer (CRC), confirm the underlying mucus hypothesis, and assess patient acceptability while developing a valuable biobank of samples. The study successfully validated Oricol’s multi-modal detection methodologies, including mutation, methylation, and microbiome analysis. The results underpin the ongoing publication process in Nature Cancer and will inform the design of Oricol Triage v1, a prototype diagnostic to evaluate disease performance.